Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3012707547, Las Vegas, Nevada, United States. Part of Predictive Biotech's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 2
Official action indicated: 0
Last inspection ended: Jun 11, 2021
Warning letters: 2
Inspections by Fiscal Year
FY2018 to FY2027 to date; 0 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 1271.55(a)(2): Eligibility statement--basis of determination1
Inspections
2 inspections, newest first
Jun 11, 2021
Biologics · Vaccines and Allergenic ProductsBiologics · Human Cellular, Tissue, and Gene Therapies; Biologics · Blood and Blood Products
10 cited references
21 CFR 211.80(a). Procedures To Be in Writing Written procedures are lacking which describe in sufficient detail the receipt and approval of components.
21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
21 CFR 211.188(b). Batch production and Batch Control Record Requirements The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in processing.
21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
21 CFR 211.166(a). Lack of written stability program There is no written testing program designed to assess the stability characteristics of drug products.
21 CFR 1271.50(a). Determination based on screening and testing HCT/P donors were not determined to be eligible based on the results of donor screening and testing.
21 CFR 211.113(b). Validation lacking for sterile drug products Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic process.
21 CFR 1271.55(a)(2). Eligibility statement--basis of determination After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.
21 CFR 211.42(c)(10)(v). Cleaning System Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
21 CFR 211.170(b)(1). Retention time of reserve samples, in general You did not retain reserve samples for drug products for one year after the expiration dates of the drug products.
No Action Indicated (NAI)
Oct 23, 2017
Biologics · Human Cellular, Tissue, and Gene TherapiesBiologics · Blood and Blood Products
2 cited references
21 CFR 1271.270(a). Records incomplete Records were not detailed as necessary to provide a complete history of work performed.
21 CFR 1271.270(a). Records maintained concurrently Records were not maintained concurrently with the performance of each step.
Voluntary Action Indicated (VAI)
Warning Letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm.FDA Data Dashboard, warning letters and enforcement reports